WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Ralph Lauren goes minimal for latest fashion show, with muted tones and a more intimate setting
Silk culture festival and temple fair parade held in Huzhou
British jets shoot down Iranian drones over Syrian border
China launches campaign to combat movie piracy during Spring Festival holiday
Refugee agency chief warns that the number of Syrians leaving Lebanon is likely to rise
Underwater dragon dance staged in China's Qingdao
New Yorkers wrap up Lunar New Year celebrations with big parades
Update on Ashlee Good's baby who was stabbed in Westfield Bondi stabbing rampage
Bizarre moment yacht gets wedged underneath railway arches while being carried on a low
Athletic Bilbao celebrates Copa trophy before being held to 1
Immigrant's $1.3B Powerball win spotlights the Iu Mien community
People across China enjoy festive events to celebrate Chinese Lunar New Year